We have successfully synthesized NSC828779, a new salicylanilide derivative,demonstrated that this new compound bears high efficiencylow toxicity on: [1] inhibiting renal fibrosismononuclear leukocytes infiltration[2] inhibiting IL-36α signaling, on renal fibrosis in a mouse renal fibrosis model. Importantly, we also owned [1] three approved material patents (US 8975255 B2 US 9162993 B2 I454445, Taiwan) [2] two indication patents [US 17/308,67, USPTO, USA,T2393-TW, NDMC, Taiwan, submitted) under review [3] technology transfer to Encommelt Medical Sciences llc.